Reducing Medication Errors and Time to Drugs Delivery During Pediatric Cardiopulmonary Resuscitation: a Multicenter RCT

Summary

The investigators recruit nurses working in 5 swiss Pediatric Emergency Departments or divisions to prepare continuous infusions of vasoactive drugs during a simulation-based pediatric CPR cardiac arrest scenario. According to randomization, nurses will have to prepare and deliver vasoactive drugs following their current conventional methods or by the aim of a mobile tablet application called PedAMINES™. PedAMINES™ is designed to support them step-by-step from order to delivery of these drugs.

1. Primary outcome will be to measure in each allocation group the number of medication dosage errors committed during each drug preparation sequence until injection.
2. Secondary outcome will be to measure the time to drug preparation (TDP) and time to drug delivery (TDD).

Conditions

• Resuscitation
• Pediatrics

Interventions

DEVICE

PedAMINES™ / Conventional Method

Each nurse will be asked to prepare a 5 μg/kg/min continuous infusion of dopamine (Period 1) and then to prepare a 0.1 μg/kg/min continuous infusion of norepinephrine (Period 2) for a 25kg boy using the studied delivery devices according to the sequence randomly assigned based on a cross-over design: • PedAMINES™ (Period 1) and then Conventional Method (Period 2)

DEVICE

Conventional Method / PedAMINES™

Each nurse will be asked to prepare a 5 μg/kg/min continuous infusion of dopamine (Period 1) and then to prepare a 0.1 μg/kg/min continuous infusion of norepinephrine (Period 2) for a 25kg boy using the studied delivery devices according to the sequence randomly assigned based on a cross-over design: • Conventional Method (Period 1) and then PedAMINES™ (Period 2)

Sponsors & Collaborators

• University of Geneva, Switzerland

  collaborator OTHER

• University of Lausanne Hospitals

  collaborator OTHER

• Insel Gruppe AG, University Hospital Bern

  collaborator OTHER

• Neuchâtel Hospital, Neuchâtel, Switzerland

  collaborator UNKNOWN

• Fribourg Hospital, Fribourg, Switzerland

  collaborator UNKNOWN

• Sion Hospital, Sion, Switzerland

  collaborator UNKNOWN

• Pediatric Clinical Research Platform

  lead OTHER

Principal Investigators

• Johan N Siebert, MD · Geneva Children Hospital, Geneva University Hospitals, Geneva, Switzerland

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

CROSSOVER

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2017-03-01

Primary Completion

2017-12-31

Completion

2017-12-31

Countries

• Switzerland

Study Locations